What Researchers Did
Researchers measured blood markers of oxidative stress in patients with sudden sensorineural hearing loss who were treated with hyperbaric oxygen (HBO) therapy, and compared those who did and did not also take vitamin D (cholecalciferol, 4000 IU per day).
What They Found
This study of patients with sudden sensorineural hearing loss given HBO therapy found no statistically significant differences in oxidative stress markers between patients who did and did not receive vitamin D. Blood was collected before the first HBO procedure, within 5 minutes after it, and after 14 procedures. In patients without vitamin D, erythrocyte TBARS rose 53.2% after the first HBO treatment (p less than or equal to 0.05), and haemoglobin fell 10.9% after 14 treatments compared with baseline (p less than or equal to 0.05). In patients receiving vitamin D, erythrocyte MDA fell 27.6% after 14 treatments compared with after the first (p less than or equal to 0.05). Plasma conjugated dienes fell 33.3% after 14 treatments in both groups. Erythrocyte SOD, GPx and CAT activities and haematocrit did not change significantly.
What This Means for Canadian Patients
The study measured blood markers, not hearing recovery, so it does not show whether HBO therapy or vitamin D improves hearing. The authors describe the effect of HBO therapy on oxidative stress markers as inconclusive and complex. They say repeated HBO treatments can cause adaptive changes, and that it is possible vitamin D inhibits lipid peroxidation in red blood cells. Patients with this condition should discuss any vitamin D use with their own physician.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The abstract reports no difference between the vitamin D and non-vitamin D groups, so the vitamin D findings come from changes within groups, and the abstract does not give group sizes or report hearing outcomes.